Nektar (NKTR) Q3 2026 Earnings Call Transcript
Nektar Therapeutics Q3 2026 Earnings Call Summary
What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
Nektar: Q3 Earnings Snapshot
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M
Nektar Therapeutics to Participate in Two Investor Conferences in November
How New Eczema Drug Trials Will Impact Nektar Therapeutics (NKTR) Investors
Is Nektar Therapeutics (NKTR) Overvalued After A 407% Three Year Run?
Nektar Therapeutics: Focus Returns To The Strengths Of The Company
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating
Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.